Cite
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
MLA
Loomba, Rohit, et al. “TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.” Gastroenterology, vol. 161, no. 5, Nov. 2021, pp. 1475–86. EBSCOhost, https://doi.org/10.1053/j.gastro.2021.07.025.
APA
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., O’Farrell, M., McCulloch, W., Grimmer, K., Rinella, M., Wai-Sun Wong, V., Ratziu, V., Gores, G. J., Neuschwander-Tetri, B. A., & Kemble, G. (2021). TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology, 161(5), 1475–1486. https://doi.org/10.1053/j.gastro.2021.07.025
Chicago
Loomba, Rohit, Rizwana Mohseni, K Jean Lucas, Julio A Gutierrez, Robert G Perry, James F Trotter, Robert S Rahimi, et al. 2021. “TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.” Gastroenterology 161 (5): 1475–86. doi:10.1053/j.gastro.2021.07.025.